Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06324786

Brain Mechanisms of Reducing Polysubstance Use

The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Drug Use

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

YiYuan Tang

Phoenix, Arizona, 85004, United States

Location status: Recruiting

Location contact

YiYuan Tang

CONTACT

[email protected]

4807903577

About this study

The proposed study will test whether real-time NF could optimize IBMT practice and improve effects in reducing polysubstance use through targeting self-control networks in the brain.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years old
  • Free of any psychiatric diagnoses or medication (besides a substance use disorder (SUD) to alcohol, tobacco, or cannabis)
  • In the past month, at least 4 episodes of heavy episodic drinking; at least 3 occasions of cannabis use; and daily cigarette use for at least the past month
  • Normal or corrected-to-normal vision
  • Written informed consent
  • No previous meditation or NF experiences

Exclusion criteria

  • Any psychiatric diagnoses other than an SUD
  • Medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females)
  • Excluding cannabis, evidence of recent (past month) illicit drug use

Treatment and study plan

IBMT

Behavioral

IBMT is an effortless mindfulness technique

NF

Behavioral

NF is a mental training technique.

Primary outcomes

  1. Intervention effects on brain function using Functional Magnetic Resonance Imaging (fMRI)

    Time frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months

    Brain connectivity changes such as anterior and posterior cingulate cortex measured by fMRI resting state imaging

  2. Intervention effects on brain white matter using fMRI

    Time frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months

    Brain white matter changes such as anterior and posterior cingulate cortex measured by fMRI diffusion tensor imaging

  3. Intervention effects on brain grey matter using fMRI

    Time frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months

    Brain volume changes such as anterior and posterior cingulate cortex measured by fMRI structural imaging

Secondary outcomes

  1. Intervention effects on addiction behavior using substance use questionnaires in PhenX Toolkit

    Time frame: The outcome measures are assessed in-person at baseline, 2-4 weeks and 3 months

    Intervention leads to a significant reduction in craving and substance use measured by substance use questionnaires in PhenX Toolkit

Study contacts

Contact information is provided by the study sponsor or research team.

YiYuan Tang

CONTACT

[email protected]

4807903577

Sponsors and collaborators

Lead sponsor

Arizona State University

Other

Registry information

Official study title

Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention 2

Important dates

Study start
2023
Primary completion
2027
Study completion
2027
First posted
Mar 22, 2024
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.